Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,ELISA 1:10000,Not yet tested in other applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
OCRL
(Oculocerebrorenal Syndrome of Lowe (OCRL))
Andere Bezeichnung
OCRL
Hintergrund
OCRL, INPP5F, OCRL1, Inositol polyphosphate 5-phosphatase OCRL-1, Lowe oculocerebrorenal syndrome proteinOCRL encodes an inositol polyphosphate 5-phosphatase. OCRL, inositol polyphosphate-5-phosphatase is involved in regulating membrane trafficking and is located in numerous subcellular locations including the trans-Golgi network, clathrin-coated vesicles and, endosomes and the plasma membrane. OCRL, inositol polyphosphate-5-phosphatase may also play a role in primary cilium formation. Mutations in OCRL cause oculocerebrorenal syndrome of Lowe and also Dent disease. Alternate splicing results in multiple transcript variants.